Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VEEV 
Veeva Systems Inc Class A (VEEV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: VEEV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
32 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $300.78
1 Year Target Price $300.78
| 12 | Strong Buy |
| 7 | Buy |
| 11 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.15% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 46.82B USD | Price to earnings Ratio 60.84 | 1Y Target Price 300.78 |
Price to earnings Ratio 60.84 | 1Y Target Price 300.78 | ||
Volume (30-day avg) 32 | Beta 0.96 | 52 Weeks Range 200.30 - 296.72 | Updated Date 08/26/2025 |
52 Weeks Range 200.30 - 296.72 | Updated Date 08/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-27 | When After Market | Estimate 1.9 | Actual - |
Profitability
Profit Margin 27.34% | Operating Margin (TTM) 30.79% |
Management Effectiveness
Return on Assets (TTM) 6.9% | Return on Equity (TTM) 14.06% |
Valuation
Trailing PE 60.84 | Forward PE 38.61 | Enterprise Value 40610726014 | Price to Sales(TTM) 16.4 |
Enterprise Value 40610726014 | Price to Sales(TTM) 16.4 | ||
Enterprise Value to Revenue 14.22 | Enterprise Value to EBITDA 50.09 | Shares Outstanding 163412000 | Shares Floating 149919322 |
Shares Outstanding 163412000 | Shares Floating 149919322 | ||
Percent Insiders 8.55 | Percent Institutions 89.76 |
Upturn AI SWOT
Veeva Systems Inc Class A
Company Overview
History and Background
Veeva Systems was founded in 2007 by Peter Gassner and Matt Wallach. It focuses on cloud-based software solutions for the global life sciences industry, evolving from CRM to a broader platform offering.
Core Business Areas
- Veeva Commercial Cloud: Provides CRM, content management, and multichannel marketing solutions for commercial teams in the life sciences industry.
- Veeva Vault: A unified suite of cloud applications for managing content, data, and processes across the entire product lifecycle, from R&D to commercialization.
Leadership and Structure
Peter Gassner is the Founder and Chairman. Paul Shawah is EVP, Commercial Strategy. The organizational structure is built around product lines and customer segments.
Top Products and Market Share
Key Offerings
- Veeva CRM: A leading CRM solution tailored for the pharmaceutical industry, helping manage customer relationships and sales processes. Market share is estimated to be around 50% within its specific niche. Competitors include Salesforce Health Cloud.
- Veeva Vault EDC: Electronic Data Capture system for clinical trials, part of the Veeva Vault platform, streamlining data collection and management. Estimated revenue from Vault EDC is significant. Competitors include Medidata Rave and Oracle Clinical One.
- Veeva Vault CDMS: Provides suite of clinical applications including EDC, coding, ePRO, data management and analytics. Market share is estimated to be around 15%.
- Veeva Vault PromoMats: For commercial content and digital asset management. Veeva dominates market share for this content space.
Market Dynamics
Industry Overview
The life sciences industry is increasingly adopting cloud-based solutions to improve efficiency, compliance, and collaboration. Growth in R&D and regulatory complexity drives demand.
Positioning
Veeva is a dominant player specializing in cloud solutions exclusively for the life sciences industry. Its focus provides a competitive edge in terms of industry expertise and product customization.
Total Addressable Market (TAM)
The TAM for cloud-based solutions in the life sciences is estimated to be $20 billion. Veeva is well-positioned with its comprehensive suite of products, targeting both commercial and R&D aspects.
Upturn SWOT Analysis
Strengths
- Strong industry focus
- Comprehensive product suite
- High customer retention
- Cloud-based platform
- Regulatory expertise
Weaknesses
- Limited diversification
- Potential dependence on single industry
- Premium pricing may deter some customers
Opportunities
- Expanding into new geographies
- Developing new products and services
- Acquiring complementary technologies
- Increasing partnerships with CROs and other industry players
Threats
- Competition from larger technology vendors
- Economic downturn affecting pharmaceutical spending
- Changes in regulatory requirements
- Security breaches or data privacy concerns
Competitors and Market Share
Key Competitors
- SALESFORCE.COM INC (CRM)
- MEDIDATA SOLUTIONS (MDSO)
- ORACLE CORP (ORCL)
Competitive Landscape
Veeva's focus on the life sciences industry gives it an advantage over broader technology providers. However, it faces competition from established players with greater resources.
Major Acquisitions
Crossix Solutions
- Year: 2019
- Acquisition Price (USD millions): 520
- Strategic Rationale: To enhance Veeva's commercial cloud offerings with privacy-safe patient-level data and analytics.
Growth Trajectory and Initiatives
Historical Growth: Veeva has experienced strong revenue growth driven by increased adoption of its cloud-based solutions in the life sciences industry.
Future Projections: Analysts project continued revenue growth, driven by increasing demand for digital transformation solutions in the life sciences sector.
Recent Initiatives: Veeva is investing in new product development, expanding its partner ecosystem, and exploring opportunities in emerging markets.
Summary
Veeva Systems shows long-term growth due to its niche focus on the life science industry. It maintains a strong market position due to its customer retention and growing product offerings. The company needs to be aware of the economic downturn affecting pharmaceutical spending and competition from larger technology vendors. Overall, Veeva's revenue growth demonstrates its potential to continue expanding in the Life Science industry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and may vary. Financial data is based on publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Veeva Systems Inc Class A
Exchange NYSE | Headquaters Pleasanton, CA, United States | ||
IPO Launch date 2013-10-16 | Founder, CEO & Director Mr. Peter P. Gassner | ||
Sector Healthcare | Industry Health Information Services | Full time employees 7291 | Website https://www.veeva.com |
Full time employees 7291 | Website https://www.veeva.com | ||
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud consisting of Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; and Veeva RIM that provides regulatory information management capabilities; as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services. Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.